Prof Byoung Chul Cho speaks to ecancer at ESMO 2019 in Barcelona about the phase III ATTRACTION-3 study comparing nivolumab with chemotherapy in patients with advanced oesophageal squamous cell carcinoma (ESCC).

He explains that for patients with ESCC who have progressed on platinum based combination chemotherapy there is virtually no option in the second line setting.

He reports that the study demonstrated that nivolumab showed a superior efficacy with manageable toxicities compared to chemotherapy.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.